Please login to the form below

Not currently logged in
Email:
Password:

Immatics

This page shows the latest Immatics news and features for those working in and with pharma, biotech and healthcare.

Roche pays $1bn-plus for stake in genomics specialist

Roche pays $1bn-plus for stake in genomics specialist

In 2013 Roche licensed a series of early-stage cancer immunotherapy programmes from German company Immatics in a deal valued at more than $1bn, and promised up to $422.5m to

Latest news

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    Also, hot off the block was Amgen with the purchase of Immatics' next-generation, T-cell engaging bispecific immunotherapies. ... Immatics. Amgen. Licence / joint development. Next-generation, T-cell engaging bispecific immuno-therapies .

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    hyperactivity disorder, pain, urology and allergy. 1, 600. immatics / Roche.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics